Crosstalk between CXCR4 and CB2 in Breast Cancer
Author Information
Author(s): Nasser Mohd W. Qamri, Zahida Deol, Yadwinder S. Smith, Diane Shilo, Konstantin Zou, Xianghong Ganju, Ramesh K. Ganju
Primary Institution: The Ohio State University
Hypothesis
A synthetic non-psychoactive cannabinoid that specifically binds to cannabinoid receptor CB2 may modulate breast tumor growth and metastasis by inhibiting signaling of the chemokine receptor CXCR4.
Conclusion
The study suggests that CB2-specific synthetic cannabinoids can inhibit breast cancer growth and metastasis by blocking CXCR4/CXCL12-induced signaling.
Supporting Evidence
- High expression of both CB2 and CXCR4 receptors was observed in breast cancer patient tissues.
- JWH-015 treatment inhibited CXCL12-induced chemotaxis and wound healing in breast cancer cell lines.
- JWH-015 significantly inhibited orthotopic tumor growth in syngenic mice.
Takeaway
This study found that a special cannabinoid can help stop breast cancer from growing and spreading by blocking a specific signal in the cancer cells.
Methodology
The study used immunohistochemical analysis, chemotactic and wound healing assays, and in vivo mouse models to assess the effects of the cannabinoid JWH-015 on breast cancer cells.
Participant Demographics
The study analyzed tumor samples from 82 breast cancer patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website